Radioligand therapy expands patient access in community oncology, pairing precision imaging with safe local delivery so patients stay close to home. This commentary will appear in the May issue of Evidence-Based Oncology.
J. Tyler Middlebrooks, MS, RSO, CNMT, NMTCB(RS), RT(N)(CT), LBBH
Advertisement
J. Tyler Middlebrooks, MS, RSO, CNMT, NMTCB(RS), RT(N)(CT), LBBH, is the principal radiopharmaceutical physicist and radiation safety officer at Highlands Oncology, based in Fayetteville, Arkansas.
Articles by J. Tyler Middlebrooks, MS, RSO, CNMT, NMTCB(RS), RT(N)(CT), LBBH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
5